A phase II multicenter, randomized, placebo controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).

被引：2
|
作者：
Levy, Benjamin Philip
Giaccone, Giuseppe
Besse, Benjamin
Begic, Damir
Wu, Xiaoling
Fandi, Abderrahim
Paz-Ares, Luis
机构：
[1] Mt Sinai Hlth Syst, New York, NY USA
[2] Georgetown Univ, Washington, DC USA
[3] Gustave Roussy, Dept Med Oncol, Villejuif, France
[4] Celgene Corp, Summit, NJ USA
[5] Hosp Univ Virgen Rocio, Seville, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS9107
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9107
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase 2 Study of Pembrolizumab Plus CC-486 vs Pembrolizumab Plus Placebo in Previously Treated Patients with Advanced NSCLC
    Levy, B.
    Giaccone, G.
    Besse, B.
    Felip, E.
    Garassino, M.
    Domine, M.
    Garrido, P.
    Piperdi, B.
    Ponce Aix, S.
    Slepetis, R.
    Wu, X.
    Fandi, A.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1803 - S1804
  • [2] Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer
    Levy, Benjamin P.
    Giaccone, Giuseppe
    Besse, Benjamin
    Felip, Enriqueta
    Garassino, Marina Chiara
    Domine Gomez, Manuel
    Garrido, Pilar
    Piperdi, Bilal
    Ponce-Aix, Santiago
    Menezes, Daniel
    MacBeth, Kyle J.
    Risueno, Alberto
    Slepetis, Ruta
    Wu, Xiaoling
    Fandi, Abderrahim
    Paz-Ares, Luis
    EUROPEAN JOURNAL OF CANCER, 2019, 108 : 120 - 128
  • [3] A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC)
    Sandler, A.
    Schiller, J. H.
    Hirsh, V.
    Sequist, L. V.
    Soria, J.
    Von Pawel, J.
    Wang, Q.
    Pande, A. U.
    Schwartz, B. E.
    Garmey, E. G.
    Gorbatchevsky, I.
    Scagliotti, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Comment on 'Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer'-No support for de-escalation of immunotherapy
    Georgiou, Alexandros
    Minchom, Anna
    O'Brien, Mary
    EUROPEAN JOURNAL OF CANCER, 2019, 115 : 24 - 26
  • [5] Niraparib (Nira) plus Pembrolizumab (Pembro) versus placebo (PBO) + Pembro 1L maintenance therapy in advanced non-small cell lung cancer (NSCLC): ZEAL-1L phase 3 study
    Schuler, M.
    Ramalingam, S.
    Arora, S.
    Neibauer, Whipple M.
    Zho, J.
    Hazard, S.
    Frenkl, T.
    Stojadinovic, A.
    Peters, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 170 - 171
  • [6] First-line (1L) maintenance therapy with niraparib (nira) plus pembrolizumab (pembro) vs placebo plus pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase 3 ZEAL-1L study
    Nagrial, Adnan
    Ramalingam, Suresh S.
    de Castro, Gilberto, Jr.
    Garassino, Marina Chiara
    Mazieres, Julien
    Sanborn, Rachel
    Smit, Egbert
    Spigel, David R.
    Thomas, Michael
    Velcheti, Vamsidhar
    Shi, Lei
    Neibauer, Melissa Whipple
    Stojadinovic, Alexander
    Peters, Solange
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 204 - 205
  • [7] First-line (1L) maintenance therapy with niraparib (nira) plus pembrolizumab (pembro) vs placebo plus pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase III ZEAL-1L study
    Ramalingam, S. S.
    de Castro, G., Jr.
    Garassino, M. C. C.
    Mazieres, J.
    Sanborn, R. E.
    Smit, E. F. F.
    Spigel, D. R.
    Thomas, M.
    Velcheti, V.
    Zhi, E.
    Whipple Neibauer, M.
    Stojadinovic, A.
    Peters, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1030 - S1032
  • [8] Niraparib (Nira) plus Pembrolizumab (Pembro) Versus Placebo (PBO) plus Pembro first line (1L) Maintenance Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): ZEAL-1L Phase 3 Study
    Schuler, Martin
    Ramalingam, Suresh S.
    Shi, Lei
    Neibauer, Melissa Whipple
    Frenkl, Tara
    Stojadinovic, Alexander
    Peters, Solange
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 152 - 152
  • [9] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (PBO) plus chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC).
    Cortes, Javier
    Guo, Zifang
    Karantza, Vassiliki
    Aktan, Gursel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [10] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (PBO) plus chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
    Cortes Castan, J.
    Guo, Z.
    Karantza, V.
    Aktan, G.
    ANNALS OF ONCOLOGY, 2017, 28
12345